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transfection method for studying gene function
and bone growth in human primary cranial
suture mesenchymal cells reveals that the cells
respond to BMP2 and BMP3
Prem P Dwivedi1,2, Peter J Anderson1,2,3† and Barry C Powell1,2*†Abstract
Background: Achieving efficient introduction of plasmid DNA into primary cultures of mammalian cells is a
common problem in biomedical research. Human primary cranial suture cells are derived from the connective
mesenchymal tissue between the bone forming regions at the edges of the calvarial plates of the skull. Typically
they are referred to as suture mesenchymal cells and are a heterogeneous population responsible for driving the
rapid skull growth that occurs in utero and postnatally. To better understand the molecular mechanisms involved in
skull growth, and in abnormal growth conditions, such as craniosynostosis, caused by premature bony fusion, it is
essential to be able to easily introduce genes into primary bone forming cells to study their function.
Results: A comparison of several lipid-based techniques with two electroporation-based techniques demonstrated
that the electroporation method known as nucleofection produced the best transfection efficiency. The parameters
of nucleofection, including cell number, amount of DNA and nucleofection program, were optimized for
transfection efficiency and cell survival. Two different genes and two promoter reporter vectors were used to
validate the nucleofection method and the responses of human primary suture mesenchymal cells by fluorescence
microscopy, RT-PCR and the dual luciferase assay. Quantification of bone morphogenetic protein (BMP) signalling
using luciferase reporters demonstrated robust responses of the cells to both osteogenic BMP2 and to the anti-
osteogenic BMP3.
Conclusions: A nucleofection protocol has been developed that provides a simple and efficient, non-viral
alternative method for in vitro studies of gene and protein function in human skull growth. Human primary suture
mesenchymal cells exhibit robust responses to BMP2 and BMP3, and thus nucleofection can be a valuable method
for studying the potential competing action of these two bone growth factors in a model system of cranial bone
growth.
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Table 1 Analysis of transfection efficiency of human
primary calvarial suture mesenchymal cells by lipid-based
transfection methods
Transfection Method % Cell Survival % Transfection Efficiency
Turbofect ND 1.5±0.2





ND=not determined. Values ± SD represent the mean of 3 biological
replicates.
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The ability to transfect DNA into mammalian cells is vital
in biomedical research, particularly in studies of mechan-
istic understanding and clinical application. In particular,
functional analyses of proteins, their trafficking and
localization, gene expression studies, tissue engineering
and gene therapy frequently require introduction of plas-
mid DNA into mammalian cells. Some questions can be
addressed using transformed cell lines but they are artifi-
cial models harbouring one or more oncogenic mutations
that may have had widespread and poorly characterized
effects on cellular biology, and reliance on their use alone
can distort views of function and significance. In contrast,
primary cultured cells are non-transformed and typically
comprise a mixed population that is more representative
of the cellular complexity of the tissue of origin. However,
lipid-based methods commonly used to transfect trans-
formed cells are generally ineffective with primary cells
and achieving efficient transfection of primary cells is a
common problem in biomedical research. The two major
alternatives to lipid-based methods for introducing genes
into cells are viral transduction and electroporation. Al-
though viral transduction can be effective, construction
and handling of viral vectors and the processes involved in
transduction are time consuming and require specialist
expertise and, in cases of clinical application, safety issues
can become paramount [1-4]. Non-viral electroporation of
genes into primary cells can provide a simple and efficient
alternative but, typically, primary cells of different origins
cannot necessarily be transfected using the same condi-
tions, which then need to be optimized [5-10].
Growth of the skull vault occurs via a different process
to that of long bone growth and less is known about the
mechanisms involved. Whereas growth of long bones
occurs via a two step process (known as endochondral
ossification) in which chondrogenesis precedes osteo-
genesis [11-13], growth of the calvarial plates of the skull
vault occurs via direct differentiation of mesenchymal
osteoprogenitor cells into bone-forming osteoblasts. This
occurs at the fibrous suture located between calvaria and
is known as intramembranous ossification [13]. Prema-
ture bony fusion of cranial sutures results in craniosy-
nostosis, a developmental disorder that affects one in
2500 live births [14], with dramatic consequences for
affected children, including raised intracranial pressure,
impaired vision and hearing, intellectual disability and
psychological problems associated with different head
shapes [15-18]. Human primary calvarial suture mesen-
chymal cells derived from the bone forming regions be-
tween the skull calvarial plates can be used to study the
molecular mechanisms involved in skull growth and the
premature bony fusion that characterizes craniosynosto-
sis [19-21] in the pursuit of biologically-based, adjunct-
ive therapies to minimize the need for recurrent surgicalcorrection during early childhood development. How-
ever, lack of an efficient method for transfection limits
progress towards this goal.
In this study we compared lipid-based and
electroporation-based techniques to introduce genes into
human primary calvarial suture mesenchymal cells and
have shown that an optimized electroporation-based
nucleofection technique provides the most effective and
reliable transfection. We have conducted benchmark
experiments to validate gene expression and study func-
tion using glypican 3 (Gpc3) a proteoglycan capable of
regulating a variety of growth factors [22], and to measure
cell responses to two important bone growth factors, bone
morphogenetic protein 2 (BMP2) and BMP3, which have
antagonistic roles in bone growth [23,24].
Results
Transfection of human primary calvarial suture
mesenchymal cells using the Amaxa Nucleofector- II
Initially, for transfection of human primary calvarial su-
ture mesenchymal cells we tested several lipid-based,
commercial transfection agents with a Green Fluores-
cent Protein (GFP)-containing expression construct,
pmaxGFP (Table 1). None of the transfection agents, ex-
cept endofectine and metafectine, showed any significant
cell death as observed by light microscopy but the per-
centage of GFP-positive cells determined by flow cyto-
metry indicated that these agents produced only 1-4 %
transfection efficiency (Table 1). As a result of these very
low transfection efficiencies, we tested electroporation-
based methods using the Neon transfection system and
the Amaxa Nucleofector II system. Using the Neon
transfection system with human primary cranial suture
mesenchymal cells, at best we achieved a transfection ef-
ficiency of 10 % (data not shown) with recommended
amounts of plasmid DNA (500 ng pmaxGFP) and cells
(100,000), and recommended optimization protocols
that varied pulse voltage (850-1600 V), pulse width (10–
40 ms) and pulse number (one to three pulses). In
contrast, with the Amaxa Cell Line Optimization
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were achieved using program T030 and nucleofector
solution-V (35 %) and nucleofector solution-L (56 %);
however, cell survival was variable (Table 2). To optimize
transfection efficiencies and cell survival we tested sev-
eral other nucleofector kits (Basic Nucleofector Kit for
Primary Mammalian Epithelial Cells and Cell Line
Nucleofector Kit T for Bone Marrow) which have been
used to transfect primary cells from other tissues. We
never achieved transfection efficiencies above 10 % using
these kits (data not shown). Therefore, we optimized
plasmid concentration and cell number using the T030
program and nucleofector solution-L, which had initially
produced the highest transfection efficiency in the
human primary suture cells. We tested 3, 6 and 9 μg of
pmaxGFP per transfection and found that increasing
amounts of plasmid resulted in lower cell survival
(Table 3). However, transfection efficiency was higher
with more plasmid and the total number of transfected
cells obtained with either 3 or 6 μg plasmid was similar.
Next, we investigated transfection efficiency and cell sur-
vival using increasing cell numbers in the transfection
mix (Table 4). Increasing cell numbers resulted in lower
cell survival but higher transfection efficiency. The high-
est relative numbers of living transfected cells were
achieved with inputs of 0.5 x 106 and 1 x 106 cells with
3 μg of plasmid. Figure 1 shows GFP fluorescence in liv-
ing, transfected cells.
Validation of the nucleofection method demonstrates
cellular responses to BMP2 and BMP3 in human primary
calvarial suture mesenchymal cells
To demonstrate expression from other transfected plasmids
and test functional responses in the cells, we first nucleo-
fected a Gpc3 expression vector into primary human
calvarial suture mesenchymal cells using nucleofection.
Expression of the nucleofected Gpc3 was confirmed by RT-Table 2 Effect of specific nucleofection programs on cell surv
calvarial suture mesenchymal cells
V- Nucleofector buffer
Nucleofection program pmaxGFP (μg) % Cell survival % Tra
No-Program control 3μg 99.2 0.2
T-030 No GFP control 26 0.3
T-030 3μg 14 35.5
A-020 3 μg 20 10.4
T-020 3 μg 14 22.7
X-001 3 μg 24 12.8
X-005 3 μg 24 16.5
L-029 3 μg 11 23.5
D-023 3 μg 15 27.2
Values ± SD with * represent the mean of 2 independent experiments, each with 2
with 2 biological replicates.PCR (Figure 2). Next, cell function studies were conducted
using the dual luciferase assay to test cell responses to two
growth factor responsive luciferase reporter constructs,
pID183-Luc and p3TP-Lux, responsive to BMP2 [25] and
BMP3 [26] respectively. Twenty-four hrs post-transfection
of pID183-Luc, BMP2 was added to transfected cells and
luciferase activity of the BMP2 responsive construct was
measured 8, 16, 24 or 48 hrs later. Maximal induction (4.5
fold) occurred 24 hrs post BMP2 treatment (Figure 3A). To
investigate responses to BMP3, cells were transfected with
p3TP-Lux and 24 hrs later BMP3 was added, then lucifer-
ase activity was assayed a further 24 hrs later. A dose of
50 ng/ml of BMP3 produced a 2 fold induction in luciferase
activity (Figure 3B).
Discussion
Inefficient introduction of plasmid DNA into primary cul-
tures of mammalian cells is a common and frustrating
problem in biomedical research that can restrict analyses
of gene and protein function and limit progress in the
understanding of human biology. Human primary cranial
suture mesenchymal cells are an heterogeneous cell popu-
lation derived from the bone forming regions between the
calvarial plates of the skull and are responsible for driving
the rapid skull growth that occurs in utero and postnatally.
There are reports describing gene expression profiles of
human cranial sutures in normal development and in ab-
normal medical conditions such as premature bony suture
fusion in craniosynostosis, but limited information about
how suture cell functions are regulated and the molecular
consequences of genetic mutations on them [20,27,28].
This fundamental information can typically be derived by
in vitro manipulation of gene and protein expression in
cell-based assays, approaches that require efficient, simple
and reliable cell transfection methods to enable general
implementation. Lipid-based methods used to transfect
plasmid DNA into mammalian cell lines are generally notival and transfection efficiency of human primary
L- Nucleofector buffer










from biological replicates. The other values are derived from one experiment
Table 3 Effect of increasing plasmid concentration on cell
survival and transfection efficiency using kit-L and the
T030 program
Program pmaxGFP (μg) % Cell survival % Transfection efficiency
T-030 No GFP control 36.0 ±4.2* 0.7 ±0.2*
T-030 3 μg 19.0 ±1.2* 60.2 ± 6.7*
T-030 6 μg 13 90.8
T-030 9 μg 10 81.4
Values ± SD with * represent the mean of 3 independent experiments, each
with 3 biological replicates. The other means are derived from one experiment
with 3 biological replicates.
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widely used lipid reagents demonstrated, and alternate
methods based on electroporation have been developed.
Since its first report 25 years ago by Chu et al. [29], elec-
troporation of mammalian cells has been modified and
developed as a commercially available technology for use
in studying difficult to transfect cell types. However, pri-
mary cells of different origins respond differently, and
methods need to be carefully optimized for each cell type.
We evaluated two electroporation-based technologies, the
Neon transfection system based on methodological
advances developed by Kim et al. [30] and the Amaxa
Nucleofector II system based on methodology developed
by Amaxa GmbH in 1998. Using the Neon transfection
system with human primary cranial suture mesenchymal
cells, at best we achieved a transfection efficiency of 10 %,
much lower than other studies using this system with
human stem cells from bone marrow, adipose tissue and
umbilical cord blood, where transfection efficiencies of 35-
80 % have been reported [31-33]. In contrast, with the
Amaxa Nucleofector II, transfection efficiencies of up to
90 % were attained, although cell survival varied with the
transfection kits and programs tested. With optimization
of transfection program, transfection solution, amount of
plasmid DNA and cell numbers, a protocol was developed
that resulted in an average of 60 % transfection efficiency
with 20 % cell survival. This transfection efficiency is com-
parable to that achieved in other primary cells and in stem
cells using the Amaxa Nucleofector or other electropora-
tors [34-39]. Although mortality of the human primary su-
ture mesenchymal cells is higher compared to other cell
types, sufficient numbers of transfected cells can beTable 4 Effect of increasing cells on cell survival and transfec
Program Cells pmaxGFP (μg) % Cell survival
T-030 500,000 No GFP control 36.0 ±4.2*
T-030 500,000 3 μg 19.0 ±0.8*
T-030 1,000,000 3 μg 13.0 ±1.0#
T-030 1,500,000 3 μg 11.0 ±1.2#
Values ± SD with * represent the mean of 4 independent experiments, each with 4
experiments, each with 2 biological replicates.obtained for quantitative-based assays of gene and protein
function, as demonstrated using the dual luciferase assay.
BMP2 is the best known bone osteogenic factor and
induces osteoblastic differentiation of multipotent mes-
enchymal cells [40,41]. In contrast, BMP3, a less well
known BMP, antagonizes BMP2 action by competing for
binding to a common effector, SMAD4 [42,43]. Loss of
BMP3 results in excessive bone formation [42,43] and
recent data show BMP3 suppresses osteoblastic differen-
tiation and thereby is thought to limit the differentiation
of osteoprogenitors [24]. Human primary suture cells
have an osteoprogenitor-like phenotype and can be
induced to differentiate with standard osteogenic supple-
ments, ascorbic acid and β-glycerophosphate [19,21].
Cranial sutures express BMP2 [21,44] and BMP3 [45]
and we used nucleofection of human primary suture
cells to measure BMP2 and BMP3 signalling with luci-
ferase reporter plasmids and demonstrate robust
responses of the cells to both BMPs. It is possible that
an interplay of these two BMPs may occur in vivo to in-
fluence in cranial bone growth, in which case that could
provide an opportunity to manipulate and alter the out-
come of abnormal bone growth in conditions such as
craniosynostosis.
Conclusions
A nucleofection protocol has been developed that pro-
vides a simple and efficient, non-viral alternative method
for in vitro studies of gene and protein function in human
skull growth. Human primary suture mesenchymal cells
exhibit robust responses to BMP2 and BMP3, and thus
nucleofection can be a valuable method for studying the
potential competing action of these two bone growth fac-
tors in a model system of cranial bone growth.
Methods
Human primary calvarial suture mesenchymal cells
Human primary calvarial suture mesenchymal cells, a
heterogeneous population derived from the connective
mesenchymal tissue between the bone forming regions
at the edges of the calvarial plates of the skull, were
grown from human suture samples as described previ-
ously [21] and were obtained from patients undergoing
surgical treatment for craniosynostosis at the Australiantion efficiency using the cell line L kit and T030 program





biological replicates and values with # represent the mean of 2 independent
Mock GFP
Figure 1 Microscopic analysis of nucleofected GFP in human primary calvarial suture mesenchymal cells. Human primary calvarial suture
cells (1.0 x 106) were transfected with 3 μg of pmaxGFP expression construct using Amaxa kit-L and the T030 program. The cells were imaged by
light microscopy.
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pital, Adelaide, South Australia. This work was approved
by the Research Ethics Committee of the Women’s and
Children’s Hospital (REC1033/10/2014) and was per-
formed in compliance with the Helsinki Declaration for
research involving human subjects. Written, informed
consent was obtained from the child, parent or guardian
according to the guidelines of the Research Ethics Com-
mittee of the Women’s and Children’s Hospital. Briefly,
for experimental purposes, cells were grown in minimal
medium (MM) consisting of high glucose Dulbecco’s




Figure 2 Expression of nucleofected Gpc3. Human primary
calvarial suture cells (1.0 x 106) were transfected with 3 μg of mouse
Gpc3 expression construct using Amaxa kit-L and the T030 program.
The amplified PCR product (174 bp) shows the expression of mouse
Gpc3 while no template controls (NTC) shows no bands. The
positions of 100 and 200 bp markers of a DNA ladder are indicated.Technologies, Gaithersburg, MD), supplemented with L-
Glutamine (584 mg/l), 10 % foetal bovine serum (Invi-
trogen, Carlsbad, CA, USA), 1 % antibiotics (penicillin
100 IU/ml), streptomycin (100 μg/ml) and 1 % anti-
biotic:antimycotic (both purchased from Sigma-Aldrich,
MI, USA) by incubating at 37°C in an humidified incu-
bator with 5 % CO2 in air. The cultures comprise cells
from the suture mesenchyme and adjacent bone growth
fronts that exhibit a pre-osteoblastic or osteoprogenitor
phenotype.
Transfection of human primary calvarial suture
mesenchymal cells using various lipid-based methods
In preparation for transfection using various lipid based
methods, cells were grown in 175 cm² flasks to 70-80 %
confluency. On the day of transfection, cells were
washed once with PBS and trypsinized by adding 2 ml of
1X trypsin (Sigma-Aldrich, St Louis, USA) and incubat-
ing the flask at 37°C for 2 mins. The cells were stained
with trypan blue and counted using a haematocytometer.
Transfections using DOTAP (N-[1-(2,3-Dioleoyloxypro-
pyl] N,N,N -trimethyl ammonium methyl sulfate; Roche
Applied Biosciences, Indianapolis, USA), Lipofectamine
2000 (Life Technologies, Invitrogen, Australia), Turbo-
fect (Fermentas Inc., Maryland, USA), X-Fect (Clontech
Laboratories Inc., CA, USA), Endofectine (GeneCopoeia
Inc., MD, USA) and Metafectine (Biontex Laboratories,
GMbH, Germany) were carried out as described in man-
ufacturer’s supplied protocols and as previously
described [46-48]. Briefly for transfection, human pri-
mary suture cells (50,000 cells / well) were seeded in a
24-well tray and grown in 400 μl of minimal medium
supplemented with 10 % fetal bovine serum. The cells
were attached by incubating at 37°C for 24 hrs. For each
triplicate transfection, 750 ng pmaxGFP (green fluores-
cent protein) expression construct (3.49 kb: Amaxa





























Figure 3 Functional analysis of nucleofected BMP2 and BMP3-responsive promoter reporters. Human primary calvarial suture cells (1.0 x
106) were nucleofected with 3 μg of BMP2 responsive promoter construct (pID183-luc; 3A) or BMP3 responsive promoter construct (p3TP-lux-Luc;
3B) using Amaxa kit-L and the T030 program. The cells were also co-nucleofected with pRL-TK-luc construct as an internal control for transfection
efficiency. Each construct was incubated with BMP2 or BMP3 or vehicle as indicated in the figures. The fold induction shown is the ratio of
luciferase activity from BMP2-treated or BMP3-treated to vehicle treatment (ie no BMP) at the appropriate time point. In Figure 3A, * shows
responses that are significantly different to vehicle, and to BMP2 treatment at 8 hrs, and # shows that 24 hrs BMP2 treatment is significantly
different to all other time-points and treatments. In Figure 3B, * shows that the response to 50 ng/ml BMP3 is significantly different compared to
vehicle and to the lower BMP3 dose. The data shows a representative result from three independent experiments, each performed with triplicate
biological samples.
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of 20 mM Hepes buffer pH 7.4 in an eppendorf tube
and, in another tube, the specific transfection agent was
diluted with 30 μl of Hepes buffer to the recommended
concentrations. The contents of these tubes were mixed
and incubated at room temperature for 20 mins for
DNA-lipid complex formation and 20 μl of this complex
was aliquotted into three wells of a 24-well tissue culture
tray. The next day the medium was removed and the
cells washed once with 400 μl of phosphate-buffered sa-
line (PBS) and replaced with 400 μl of medium, then
incubated at 37°C for another 24 hrs. Microscopy of the
GFP-transfected cells was carried out using a Nikon
Eclipse TE2000U inverted microscope attached with
twin CCD cameras and 20x objective. Cells were then
counted as indicated in the appropriate figure legends in
an haematocytometer after trypan blue staining to calcu-
late cell survival. Flow cytometric analysis of GFP-
positive cells was conducted to determine transfection
efficiency.
Flow cytometry
The expression vector, pmaxGFP, was transfected or
nucleofected into human primary calvarial suture mes-
enchymal cells. At 24 hrs post transfection cells were
washed twice with PBS and dislodged from the tissue
culture plates with 1X trypsin. Cells were thencentrifuged at 1300 rpm for 10 mins and resuspended in
100 μl of PBS. 10 μl of these cells were used for trypan
blue staining to calculate cell survival and 90 μl of the
cells were further diluted to 200 μl in PBS for analysis of
transfection efficiency by flow cytometry. GFP fluores-
cence was analyzed using a BD Bioscience FACS-AriaII.
Dead cells were gated out using 7-Aminoactinomycin D
(7-AAD) (5 μg/ml) staining. Data were analyzed using
Flowjo Version 7 (Free Star Inc., USA).
Nucleofection of human primary calvarial suture
mesenchymal cells using Amaxa transfection kits
Nucleofection of human primary calvarial suture mesen-
chymal cells was carried out using the Amaxa-II Nucleo-
fector method and available transfection kits. No kit was
specifically available for the human primary calvarial su-
ture mesenchymal cells under investigation in this study;
therefore the Amaxa Cell Line Optimization Nucleofec-
tor Kit was tested for nucleofection of human primary
suture cells. Briefly, in preparation for nucleofection, su-
ture cells were dislodged from the tissue culture flask by
trypsin and counted in a haematocytometer after trypan
blue staining. All centrifugations were carried out with
maximum g force of 150 g. For each nucleofection,
suture cells were resuspended in 100 μl of V or L
Nucleofector solution and 20 μl of the Amaxa Supple-
ment in an eppendorf tube. The appropriate amount of
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tables and figure legends. Immediately, the mixture of
suture cells, pmaxGFP and Nucleofector solution was
transferred into an Amaxa cuvette and nucleofection
conducted using the recommended program. The
nucleofected cells were resuspended in 400 μl of min-
imal media and plated into a 24-well tissue culture tray.
The cells were incubated overnight at 37°C. The next
day the medium was removed and the cells were washed
three times with 400 μl of PBS and the medium replaced
with serum-free DMEM and the cells incubated at 37°C
for a further 24 hrs. The following day, microscopy of
the GFP-transfected cells was carried out and then cells
were trypsinized and resuspended in 100 μl of PBS. Cells
(10 μl) were counted in a haematocytometer after trypan
blue staining to calculate cell survival. The remaining
cells were analysed for GFP expression by flow cytome-
try analysis and transfection efficiency was determined.Construction of Gpc3 expression vector
A mouse ORF cDNA (1.74 kb) for glypican 3 (Gpc3) and
the gateway cloning vector, pcDNA-DEST40 (7.1 kb)
were purchased (GeneCopoeia Inc., MD, USA). Gateway
cloning was carried out essentially as described in the
manufacturer’s protocol. The construct was verified
using restriction digestion analysis and DNA sequence
analysis (Applied Biosystems, CA, USA).Gene expression analysis of nucleofected Gpc3 by RT-PCR
The Gpc3 expression construct (8.84 kb) was nucleo-
fected using optimized transfection conditions (Amaxa
transfection kit L and program T030) for human pri-
mary calvarial suture mesenchymal cells. Gpc3 nucleo-
fected cells were grown in 24 well tissue culture tray for
24 hrs then washed three times with PBS and grown
overnight. RNA was extracted using an RNAeasy mini
kit (Qiagen, CA, USA) and cDNA synthesized from
200 ng RNA using a Superscript-III First Strand Synthe-
sis kit (Invitrogen, CA, USA). Primers for Gpc3 (forward
5’-ggttagccagatcattgacaaac-3’ and reverse 5’-cttcatcatcac
cgcagtctc-3’) were synthesized (Geneworks, Adelaide,
South Australia). The primers were specific for nucleo-
fected mouse Gpc3. PCR reactions were carried out
using 2 μl cDNA, 100X SYBR green (Abgene, Epson,
UK), 1X Amplitaq PCR buffer, 2 mM MgCl2, 1 unit of
Amplitaq (Applied Biosystems, Foster City, CA, USA),
0.4 mM dNTPs (Invitrogen, Carlsbad, CA, USA) and
5.625 μM primers in 25 μl. PCR was carried out using
a Gene Amp PCR System 9700 (Applied Biosystems).
An expected PCR product (174 bp) was resolved on a
1.5 % agarose gel. The PCR product was sequenced for
confirmation (Institute of Medical and Veterinary
Sciences, Adelaide, Australia).Functional analysis of BMP2 and BMP3 using promoter-
reporter assays
For transient transfection analysis, human primary cal-
varial suture mesenchymal cells were grown in 175 cm²
flasks to 70-80 % confluency. On the day of transfection
cells were washed once with PBS and trypsinized by
adding 2 ml of 1X trypsin and incubating the flask in a
37°C incubator for 2 mins. The cells were stained with
trypan blue and counted using a haematocytometer.
Transfection was conducted using the Nucleofector kit
L and program T030. In preparation for transfection, 1.5
x 106 cells were resuspended in 100 μl of Nucleofector
transfection solution with 3 μg of a BMP responsive pro-
moter luciferase construct, pID183-Luc (5.78 kb) [25] or
a TGF beta responsive promoter luciferase construct,
p3TP-Lux (6.55 kb) [26] together with 500 ng of pRLTK-
Luc construct (4.05 kb: Promega Corporation, USA) as a
control to normalize transfection efficiency. The trans-
fected cells were transferred to 3 ml of pre-warmed
medium and 200 μl of cells were aliquotted to 96-well
plates and incubated for 24 hrs in a 37°C incubator with
5 % CO2. The following day cells were washed 3 times
with PBS and then incubated with 200 μl of serum-free
DMEM with antibiotic and BMP2 and BMP3 (R&D Sys-
tems, USA) as indicated in figure legends and cells were
cultured for up to 48 hrs. Luciferase activity in cell
lysates was determined using the Dual Luciferase Assay
kit and a Luminometer as described previously [48,49].
Statistical analysis
Results are presented as mean value of 2 to 4 biological
replicates with standard deviation (SD) where appropriate.
Specific assays were statistically analyzed using Analysis of
Variance (ANOVA). The differences were considered sig-
nificant when the P value was less than 0.05.
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